Researchers

INAGAKI Chiaki

Faculty	Department of Medicine
Researchmap	https://researchmap.jp/millions-of-crystals

Randomized phase II trial of zolbetuximab as second-line treatment in patients with claudin 18.2-positive advanced gastric/GEJ cancer with previous zolbetuximab exposure: ZELDA.
C Inagaki; E Oki; K Ando; H Hirano; M Furuta; Y Narita; T Esaki; K Murotani; H Kawakami; K Muro
ESMO gastrointestinal oncology 14 , 100416-100416, Dec. 2026
Tumor-associated calcium signal transducer 2 expression as a promising therapeutic target in esophageal squamous cell carcinoma: a combined the Cancer Genome Atlas and an institutional cohort.
Chiaki Inagaki; Hisato Kawakami; Seiichiro Mitani; Hiroshi Iijima; Ryo Matoba; Akihiko Ito; Osamu Shiraisi; Takushi Yasuda; Hidetoshi Hayashi
Esophagus : official journal of the Japan Esophageal Society 20, Sep. 2026
Intratumoral heterogeneity of intermediate CLDN18.2 expression in gastric cancer.
Yusuke Kawanaka; Chiaki Inagaki; Masaki Okura; Seiichiro Mitani; Naoki Shiraishi; Kazuko Sakai; Kazuto Nishio; Yutaka Kimura; Yasutaka Chiba; Tomoko Wakasa; Hisato Kawakami; Hidetoshi Hayashi
International journal of clinical oncology 31 (9) , 2033-2042, Sep. 2026

Safety and efficacy of eribulin mesylate in patients with advanced soft tissue sarcoma in daily practice. , Inagaki C; Shimoi T; Sumiyoshi Okuma H; Kawachi A; Sudo K; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Arakawa A; Ogawa C; Yoshida A; Fujiwara Y; Tamura K , ESMO-ASIA Congress , Dec. 2016

胃癌におけるCLDN18.2中等度発現の腫瘍内不均一性に関する研究(Intratumoral Heterogeneity of Intermediate CLDN18.2 Expression in Gastric Cancer) , 川中雄介; 稲垣千晶; 大倉將生; 三谷誠一郎; 白石直樹; 坂井和子; 西尾和人; 木村豊; 千葉康敬; 若狭朋子; 川上尚人; 林秀敏 , 日本胃癌学会総会記事 , 98回 , 922 , 922 , Mar. 2026
長期生存を得た切除不能食道癌患者における治療後に生じた他臓器癌の検討 , 渡部亮太郎; 三谷誠一郎; 大倉將生; 稲垣千晶; 谷崎潤子; 田中薫; 岩朝勤; 米阪仁雄; 林秀敏 , 日本内科学会雑誌 , 114 , 2025
がん患者・医療従事者アンケート結果から見る遠隔医療への期待と不安 , 佐藤拓弥; 川上武志; 朝山雅子; 稲垣千晶; 高山歳三; 林龍二; 松本俊彦; 佐竹悠良; 谷口浩也; 砂川優 , 日本遠隔医療学会学術大会プログラム・抄録集 , 28回 , 97 , 97 , Nov. 2024